Lutz Heinemann
Heinemann, Lutz
VIAF ID: 314900426 (Personal)
Permalink: http://viaf.org/viaf/314900426
Preferred Forms
- 100 1 _ ‡a Heinemann, Lutz
-
- 100 1 _ ‡a Heinemann, Lutz
- 100 1 _ ‡a Heinemann, Lutz
-
- 100 0 _ ‡a Lutz Heinemann
4xx's: Alternate Name Forms (4)
Works
Title | Sources |
---|---|
Aktiv gegen Diabetes mit dem P.A.T.E-AktivBuch zu neuen Lebensgewohnheiten ; das P.A.T.E-Programm ; [das P.A.T.E-AktivBuch für Menschen mit Typ-2-Diabetes] | |
The digital/virtual diabetes clinic : the future is now - recommendations from an International Panel on Diabetes Digital Technologies Introduction | |
Insulin absorption from lipodystrophic areas: a | |
Insulin pens and new ways of insulin delivery | |
Insulin Pump and CGM Usage in the United States and Germany: Results of a Real-World Survey With 985 Subjects | |
Insulin Pump Occlusions: For Patients Who Have Been Around the | |
Insulin pump risks and benefits: a clinical appraisal of pump safety standards, adverse event reporting, and research needs: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Techn | |
Insulin pump therapy: what is the evidence for using different types of boluses for coverage of prandial insulin requirements? | |
Integrated personalized diabetes management improves glycemic control in patients with insulin-treated type 2 diabetes: Results of the PDM-ProValue study program | |
Interferences and Limitations in Blood Glucose Self-Testing: An Overview of the Current Knowledge | |
Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin | |
Lipohypertrophy and the artificial pancreas: is this an issue? | |
Measuring glucose concentrations: daily practice, current and future developments | |
Modeling of Diabetes and Its Clinical Impact | |
New Insulins, Biosimilars, and Insulin Therapy. | |
Noninvasive Continuous Monitoring of Vital Signs With Wearables: Fit for Medical Use? | |
Noninvasive glucose monitoring systems: will we ever have such sensors for practical use? | |
Open source automated insulin delivery: addressing the challenge | |
Optimizing insulin pump therapy: the potential advantages of using a structured diabetes management program | |
Options for the Development of Noninvasive Glucose Monitoring: Is Nanotechnology an Option to Break the Boundaries? | |
Oral insulin and buccal insulin: a critical reappraisal | |
Oral insulin reloaded: a structured approach | |
Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report | |
An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins | |
Parameters affecting postprandial blood glucose: effects of blood glucose measurement errors | |
Patch pump versus conventional pump: postprandial glycemic excursions and the influence of wear time | |
Patch Pumps: Are They All the Same? | |
Performance of Blood Glucose Meters in the Low-Glucose Range: Current Evaluations Indicate That it is not Sufficient From a Clinical Point of View. | |
Pharmacokinetic and Pharmacodynamic Properties of a Novel Inhaled Insulin | |
Pharmakokinetik und Pharmakodynamik verschiedener Insulinpräparationen und Insulin-Analoga | |
Pilots and Diabetes Technology. | |
Prediction of the risk to develop diabetes-related late complications by means of the glucose pentagon model: analysis of data from the Juvenile Diabetes Research Foundation continuous glucose monitoring study | |
Preulcerous Risk Situation in Diabetic Foot Syndrome: Proposal for a Simple Ulcer Prevention Score | |
PRIMAS Patientenset | |
Products for Monitoring Glucose Levels in the Human Body With Noninvasive Optical, Noninvasive Fluid Sampling, or Minimally Invasive Technologies | |
PsychDT Working Group: Report Psychosocial Aspects of Artificial Pancreas Systems | |
Quality Control of Insulins and Biosimilar Insulins: What Do We Know? | |
Quality of glucose measurement with blood glucose meters at the point-of-care: relevance of interfering factors | |
Quality of HbA1c Measurement in the Practice: The German Perspective | |
A rapid and reliable semiautomated method for measurement of total abdominal fat volumes using magnetic resonance imaging. | |
Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. | |
Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin | |
Replacement of Blood Glucose Measurements by Measurements With Systems for Real-Time Continuous Glucose Monitoring (rtCGM) or CGM With Intermittent Scanning (iscCGM): A German View. | |
Residual beta cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial | |
Reviewer: an endangered species?! | |
Role of physicians in the pharmaceutical industry and clinical research organizations: take more pride in your work | |
sabbu | |
Selbstbestimmt leben mit Insulin | |
Self-monitoring of blood glucose in noninsulin-treated patients with type 2 diabetes: a never ending story? | |
Significance and Reliability of MARD for the Accuracy of CGM Systems | |
So wirkt mein Insulin Insulinschablonen | |
SPECTRUM. | |
Subcutaneous injection versus subcutaneous infusion of insulin: are the rates of absorption truly the same? | |
System accuracy of blood glucose monitoring systems: impact of use by patients and ambient conditions | |
The systemic immune network in recent onset type 1 diabetes: central role of interleukin-1 receptor antagonist (DIATOR Trial). | |
Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin | |
Time Delay of CGM Sensors: Relevance, Causes, and Countermeasures | |
Toward Development of Psychosocial Measures for Automated Insulin Delivery | |
Translational research methods for diabetes, obesity and cardiometabolic drug development, [2015]: | |
Trust: need for an improved communication between the public world and the pharmaceutical companies | |
Type 2 diabetes phenotype and progression is significantly different if diagnosed before versus after 65 years of age. | |
Ultrafast-acting insulins: state of the art | |
Usability of Medical Devices for Patients With Diabetes Who Are Visually Impaired or Blind | |
Usage of Hydrocolloid-Based Plasters in Patients Who Have Developed Allergic Contact Dermatitis to Isobornyl Acrylate While Using Continuous Glucose Monitoring Systems | |
Variability of insulin absorption and insulin action | |
We Need More Research and Better Designs for Insulin Infusion Sets | |
What Are the Next Steps in Continuous Glucose Monitoring? | |
Will Biosimilar Insulins Be Cheaper? | |
Wirkprofile von Insulin-Präparationen |